Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2015 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Long-Term Investments for 12 consecutive years, with $121.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 76.48% year-over-year to $121.0 million; the TTM figure through Mar 2026 stood at $121.0 million (up 76.48% YoY), while the FY2025 annual figure was $57.0 million, down 57.78% from the prior year.
• Long-Term Investments climbed to $121.0 million in Q1 2026 per RARE's latest filing, from $57.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $215.5 million in Q1 2022 and bottomed at $22.1 million in Q3 2025.
• Historically, Long-Term Investments has averaged $117.3 million across 5 years, with a median of $110.7 million in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Investments soared 164.05% — and 2025, when it plunged 89.13%.
• Ultragenyx Pharmaceutical's Long-Term Investments stood at $149.0 million in 2022, then soared by 34.19% to $199.9 million in 2023, then tumbled by 32.47% to $135.0 million in 2024, then slumped by 57.78% to $57.0 million in 2025, then jumped by 112.28% to $121.0 million in 2026.
• Business Quant data shows RARE's Long-Term Investments at $121.0 million in Q1 2026, $57.0 million in Q4 2025, and $22.1 million in Q3 2025.